{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-128263","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.123368+00:00","generated_at":"2026-06-21T02:18:18.497788+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novavax launches $150M convertible notes (5% due 2027) and 6.5M share offering at $10","bullets":["Common stock offering of 6.5M shares at $10.00; underwriters fully exercised option for 975k additional shares.","Convertible notes offering upsized to $150M aggregate principal; initial purchasers granted option for $25.25M more.","Notes bear 5.00% interest, mature Dec 15, 2027; initial conversion price $12.50 per share (25% premium to stock offering price).","Both offerings expected to close Dec 20, 2022; neither is contingent on the other."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-128263","json":"https://secwatch.observer/filing/0001104659-22-128263.json","markdown":"https://secwatch.observer/filing/0001104659-22-128263.md","text":"https://secwatch.observer/filing/0001104659-22-128263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922128263/0001104659-22-128263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922128263/tm2232888d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:18:18.497788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42d4631448a5b3dd0b0f334d032ddb41876af405","claim":"NOVAVAX INC entered into Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters valued at 6,500,000 shares of common stock at a public offering price of $10.00 per share (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, Novavax, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to the public offering by the Company of 6,500,000 shares of its common stock, par value $0.01 per share (“Common Stock”), at a public offering price of $10.00 per share, less underwriting discounts and commissions","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922128263/0001104659-22-128263-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters"},{"label":"Value","value":"6,500,000 shares of common stock at a public offering price of $10.00 per share"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}